HEAD-TO-HEAD

5-AMINO-1MQ VS NAD+

5-amino-1MQ and NAD+ both intersect with the NAD+ longevity axis, but from opposite ends. 5-amino-1MQ is a small-molecule selective inhibitor of NNMT (nicotinamide N-methyltransferase) · blocking NNMT raises intracellular nicotinamide and SAM pools. NAD+ is the endogenous redox coenzyme itself, the obligate substrate of sirtuins, PARPs, and CD38. Indirect upstream inhibitor vs the coenzyme.

A · No. 015

5-AMINO-1MQ

Small-molecule NNMT inhibitor · body-composition research

B · No. 006

NAD+

Longevity Coenzyme

SIDE BY SIDE

FIELD

A · 5-AMINO-1MQ

B · NAD+

Class

Small-molecule NNMT inhibitor (not a peptide)

Endogenous redox coenzyme (not a peptide)

Formula

C10H11IN2 (5-amino-1-methylquinolinium iodide)

C21H27N7O14P2

Mechanism

Inhibits NNMT methylation of nicotinamide · preserves NAD+ + SAM pools

Substrate of sirtuins / PARPs / CD38 · electron-transfer cofactor in glycolysis + TCA + OXPHOS

Direction on NAD+ pool

Preserves intracellular NAD+ by blocking nicotinamide methylation

Is the NAD+ itself; precursors (NR, NMN) cross plasma membrane more efficiently

Route

Oral bioavailable in animal studies; subcutaneous (research)

Subcutaneous (research) · IV (research) · oral precursors widely used

Best evidence

Neelakantan 2017 NNMT inhibitor reduces adiposity in DIO mice (J Med Chem)

Yoshino, Imai, Baur 2018 Cell Metab review PMID 29249689; precursor trials raise NAD+ reliably

FDA status

Research chemical · not FDA-approved

Not FDA-approved as a drug; NR / NMN precursors subject to FDA enforcement actions 2022-2024

WADA status

Not listed (2026)

WHICH IS BETTER · BY GOAL

▶ Adipose body-composition researchA · 5-AMINO-1MQ

Neelakantan 2017 reported reduced adipose mass in DIO mice with 5-amino-1MQ without changes in food intake. NAD+ direct administration is not framed as a body-composition mechanism.

▶ Sirtuin / PARP axis biologyB · NAD+

Sirtuins and PARPs are NAD+-dependent enzymes; activity scales with NAD+ availability. This is direct NAD+ biology, not NNMT-inhibitor biology.

▶ Oral bioavailability for laboratory administrationA · 5-AMINO-1MQ

5-amino-1MQ is reported to be oral-bioavailable in animal studies. Direct NAD+ has poor membrane permeability; oral precursors (NR / NMN) are the practical NAD+-raising route.

▶ Established biochemistry / pathway centralityB · NAD+

NAD+ is the centerpiece of cellular bioenergetics with decades of established literature. 5-amino-1MQ is a relative newcomer (mostly preclinical, no completed human Phase 2/3).

STACKING NOTE

5-amino-1MQ and NAD+/precursors target the same downstream goal (raise intracellular NAD+) from different angles. No published RCT studies the combination; the mechanistic framing is upstream NNMT inhibition + direct precursor supplementation = combined NAD+ pool support.

SOURCED FROM GIGACOMPOUNDS

Both compounds are available as research-grade material at GigaCompounds · ≥99% purity · per-batch CoA. For laboratory research use only.

SOURCE AT GIGACOMPOUNDS ▶